RESUMEN
Objective Tocompare the clinical efficacy of Glipizide and Repaglinide in the treatment of newly diagnosed type 2 diabetes (T2DM).Methods The clinical data of 104 patients with newly diagnosed T2DM were retrospectively analyzed,among them,54 cases were treated with Glipizide (group G),and 50 eases were treated with Repaglinide (group R).The levels of FPG,2hPG,HbA1c,TC,TG and HDL-C before and after treatment and HbA1c compliance rates,BMI variation and incidences of hypoglycemia between two groups were compared.Results The levels ofFPG,2hPG and HbA1c after treatment in the two groups were significantly lower than those before treatment (P ＜ 0.05),and there were no significant difference between the groups.There were no significant changes in TG,TC and HDL-C levels before and after treatment in the two groups.There were no significant changes in HbA1c compliance rates between the two groups,and the BMI variation and incidences of hypoglycemia in the group G were significantly lower than those in the group R (P ＜ 0.05).Conclusion BothGlipizide and Repaglinide in the treatment of T2DM can reduce blood glucose effectively,and no significant effect on blood lipids,But Glipizide has more advantages in controlling BMI and reducing hypoglycemia.